Intelligent Bio Solutions (INBS) announced a strategic partnership with B2i Digital to launch an investor-focused marketing campaign. B2i Digital will employ advanced digital marketing strategies to raise awareness of INBS’ patented drug screening technology, which offers a fast, non-invasive, and efficient alternative to traditional drug tests. “As we plan for our entry into the US market, enhancing our communications and outreach to the investment community is crucial,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “Our partnership with B2i Digital allows us to connect with investors who see the potential in our unique approach to drug screening, particularly in industries where workplace safety is paramount.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INBS:
- Intelligent Bio Solutions reports Q1 preliminary revenue $0.87M
- Intelligent Bio celebrates one-year anniversary of Mount Anvil integration
- Intelligent Bio Solutions announces adoption on non-invasive drug screening
- Intelligent Bio Solutions partners with Spirit Group
- GPS Marine adopts Intelligent Bio Solutions’ Fingerprint Drug Testing technology